A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6

The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ6-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ6 levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of 18F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of 18F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7–13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98–145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time–activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: 18F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.

[1]  D. Sheppard,et al.  Integrin-mediated regulation of TGFβ in fibrosis. , 2013, Biochimica et biophysica acta.

[2]  K. Aldape,et al.  Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. , 1995, Journal of cell science.

[3]  S. Goodman,et al.  Definition of an Unexpected Ligand Recognition Motif for αvβ6 Integrin* , 1999, The Journal of Biological Chemistry.

[4]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Giancotti,et al.  Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. , 2019, Cancer cell.

[6]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  N. Kaminski,et al.  The Integrin avb6 Binds and Activates Latent TGFb1: A Mechanism for Regulating Pulmonary Inflammation and Fibrosis , 1999 .

[8]  P. Weinreb,et al.  Cyclooxygenase-2 Inhibition Suppresses αvβ6 Integrin–Dependent Oral Squamous Carcinoma Invasion , 2006 .

[9]  F. Watt,et al.  New roles for integrins in squamous-cell carcinoma , 2006, Nature Reviews Cancer.

[10]  D. Stuart,et al.  Specificity of the VP1 GH Loop of Foot-and-Mouth Disease Virus for αv Integrins , 2006, Journal of Virology.

[11]  H. Friess,et al.  Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. , 2008, Journal of hepatology.

[12]  Michael G Stabin,et al.  PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT , 2003, Health physics.

[13]  G. Edelman,et al.  Multiple integrins mediate cell attachment to cytotactin/tenascin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Oettgen,et al.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. , 2005, The Journal of clinical investigation.

[15]  M. Sporn,et al.  Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. , 1989, The American review of respiratory disease.

[16]  Stephen R Thomas,et al.  MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  D. Flint,et al.  Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2 , 2016, Pharmacology.

[18]  G. Thomas,et al.  High‐resolution in vivo imaging of breast cancer by targeting the pro‐invasive integrin αvβ6 , 2010, The Journal of pathology.

[19]  J. Sutcliffe,et al.  Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A Chelates for Targeted Positron Emission Tomography with an αvβ6-Specific Peptide , 2009 .

[20]  P. Weinreb,et al.  The αvβ6 integrin receptor for Foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle , 2005 .

[21]  A. Perkins,et al.  Preclinical SPECT/CT Imaging of αvβ6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis , 2013, The Journal of Nuclear Medicine.

[22]  Ryan A. Davis,et al.  Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma , 2018, Clinical Cancer Research.

[23]  P. Bardin,et al.  In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β. , 2016, American journal of respiratory cell and molecular biology.

[24]  J. Passchier,et al.  Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  J. Sutcliffe,et al.  Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. , 2007, Cancer research.